We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prostate cancer
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate cancer can come back after previous treatment with surgery or radiotherapy in glands (known as lymph nodes) in the pelvis, which is what happened to you. When this happens, there are different treatments that could be used for your cancer, but we do not know for certain which treatment is best. The POINTER-PC study is trying to work this out.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/39725427/ (added 17/01/2025)
You can take part if:
You may not be able to take part if:
1. Previous pelvic nodal radiotherapy2. Contraindications to SBRT or ENI (e.g. inflammatory bowel disease)3. Contraindications to ADT4. Local recurrence in the prostate gland5. Para-aortic nodal metastases (above the aortic bifurcation)6. Meso-rectal nodal metastases7. Bone or visceral metastases8. Severe late toxicity relating to primary/post-operative RT9. Other active malignancy (except non-melanoma skin cancer or other malignancy with a documented disease-free survival for a minimum of 3 years before randomisation)10. Castrate-resistant disease
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Leeds and funded by Cancer Research UK; Yorkshire Cancer Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 62335
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
